Charlene M. C. Rodrigues

Charlene M. C. Rodrigues

Auto-generated profile, based on publicly available information

Charlene M. C. Rodrigues

Affiliations Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, Department of Paediatrics, Imperial College Healthcare NHS Trust, London, United Kingdom, Pathogen Genomics Programme, UK Health Security Agency, London, United Kingdom

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CRCharlene M. C. Rodrigues
Charlene M. C. Rodrigues
SPStanley Plotkin
Stanley Plotkin
In the 20th century, the development, licensing and implementation of vaccines as part of large, systematic immunization programs started to address health inequities that existed globally. However, at the time of writing, access to vaccines that prevent life-threatening infectious diseases remains unequal to all infants, children and adults in the world. This is a problem that many individuals and agencies are working hard to address globally. As clinicians and biomedical scientists we often focus on the health benefits that vaccines provide, in the prevention of ill-health and death from infectious pathogens. Here we discuss the health, economic and social benefits of vaccines that have been identified and studied in recent years, impacting all regions and all age groups. After learning of the emergence of SARS-CoV-2 virus in December 2019, and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale. As we appreciate and quantify the health, economic and social benefits of vaccines and immunization programs to individuals and society, we should endeavor to communicate this to the public and policy makers, for the benefit of endemic, epidemic, and pandemic diseases.

1 March 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
CRC. M. C. Rodrigues
C. M. C. Rodrigues
HGHelen Elizabeth Groves
Helen Elizabeth Groves
Community-acquired pneumonia (CAP) is the leading cause of mortality in children under 5 years of age globally. To improve the management of CAP, we must distinguish CAP from other common pediatric conditions and develop better diagnostic methods to detect the causative organism, so as to best direct appropriate resources in both industrialized and developing countries. Here, we review the diagnostic modalities available for identifying viruses and bacteria in the upper and lower respiratory tract of children, with a discussion of their utility and limitations in diagnosing CAP in children.

1 September 2016 in Vaccine
Verified
Journal Article
Open access
CBCarina Brehony
Carina Brehony
CRCharlene M.C. Rodrigues
Charlene M.C. Rodrigues
RBRay Borrow
Ray Borrow
ASAndrew Smith
Andrew Smith
RCRobert Cunney
Robert Cunney
MMMartin Maiden
Martin Maiden
Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), including Bexsero®, which was implemented for UK infants in 2015, and Trumenba®. Given the diversity of meningococcal protein antigens, post-implementation surveillance of IMD isolates, including characterisation of vaccine antigens, is essential for assessing the effectiveness of such vaccines. Whole genome sequencing (WGS), as realised in the Meningitis Research Foundation Meningococcus Genome Library (MRF-MGL), provides a rapid, comprehensive, and cost-effective approach to this. To facilitate the surveillance of the antigen targets included in Bexsero® (fHbp, PorA, NHBA and NadA) for protective immunity, a Bexsero® Antigen Sequence Type (BAST) scheme, based on deduced peptide sequence variants, was implemented in the PubMLST.org/neisseria database, which includes the MRF-MGL and other isolate collections. This scheme enabled the characterisation of vaccine antigen variants and here the invasive meningococci isolated in Great Britain and Ireland in the epidemiological years 2010/11 to 2013/14 are analysed. Many unique BASTs (647) were present, but nine of these accounted for 39% (775/1966) of isolates, with some temporal and geographic differences in BAST distribution. BASTs were strongly associated with other characteristics, such as serogroup and clonal complex (cc), and a significant increase in BAST-2 was associated with increased prevalence of serogroup W clonal complex 11 meningococci. Potential coverage was assessed by the examination of the antigen peptide sequences present in the vaccine and epidemiological dataset. There were 22.8-30.8% exact peptide matches to Bexsero® components and predicted coverage of 66.1%, based on genotype-phenotype modelling for 63.7% of serogroup B isolates from 2010/14 in UK and Ireland. While there are many caveats to this estimate, it lies within the range of other published estimates.

17 December 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
CRCharlene M. C. Rodrigues
Charlene M. C. Rodrigues
KJKeith A. Jolley
Keith A. Jolley
ASAndrew Smith
Andrew Smith
JCJ. Claire Cameron
J. Claire Cameron
IFIan M. Feavers
Ian M. Feavers
MMMartin Maiden
Martin Maiden
As microbial genomics makes increasingly important contributions to clinical and public health microbiology, the interpretation of whole-genome sequence data by nonspecialists becomes essential. In the absence of capsule-based vaccines, two protein-based vaccines have been used for the prevention of invasive serogroup B meningococcal disease (IMD) since their licensure in 2013 and 2014. These vaccines have different components and different levels of coverage of meningococcal variants. Hence, decisions regarding which vaccine to use in managing serogroup B IMD outbreaks require information about the index case isolate, including (i) the presence of particular vaccine antigen variants, (ii) the expression of vaccine antigens, and (iii) the likely susceptibility of its antigen variants to antibody-dependent bactericidal killing.

23 July 2010 in Medical Teacher
Verified
Journal Article
Closed access
PDF file
ABAndrew J. Batchelder
Andrew J. Batchelder
CRCharlene M. C. Rodrigues
Charlene M. C. Rodrigues
LLLi-Ying Lin
Li-Ying Lin
PHPeter M. Hickey
Peter M. Hickey
CJChristopher Johnson
Christopher Johnson
JEJoshua E. Elias
Joshua E. Elias
Aim: This study set out to explore whether a teaching programme developed and delivered by medical students yielded an improvement of attendees’ examination performance or their experience of preparing for the target assessment. Methods: Over 4 years all students were invited to consent to use of their official examination data. Students were ranked for baseline performance and again for performance in the target assessment. Change in rank was compared for attendees and non-attenders. Additionally, a questionnaire was distributed to students before and after the peer-led programme. Attendees’ responses were compared to those of non-attenders. Results: No statistically significant difference in change in rank was observed between the two groups on evaluation of quantitative performance data. The majority of students (81.0%) scored the programme four or five in terms of perceived usefulness on a five-point Likert scale. Attendees reported statistically significant increases in preparedness for the examination (p = 0.001) and in familiarity with the style of examination questions (p = 0.004) compared to students who did not attend. Conclusion: This study suggests that teaching from peers may improve students’ perception of their preparedness for official assessments. However, such interventions may be limited in their ability to produce a demonstrable benefit in terms of examination performance.

1 June 2017 in Journal of Infection
Verified
Journal Article
Closed access
CRCharlene M.C. Rodrigues
Charlene M.C. Rodrigues
MPMarta V. Pinto
Marta V. Pinto
MSManish Sadarangani
Manish Sadarangani
SPStanley Plotkin
Stanley Plotkin